The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 10, 2006
Filed:
Sep. 29, 2000
John R. Subjeck, Williamsville, NY (US);
Robert A. Henderson, Seattle, WA (US);
Elizabeth A. Repasky, Williamsville, NY (US);
Latif Kazim, Amherst, NY (US);
Xiang-yang Wang, Buffalo, NY (US);
John R. Subjeck, Williamsville, NY (US);
Robert A. Henderson, Seattle, WA (US);
Elizabeth A. Repasky, Williamsville, NY (US);
Latif Kazim, Amherst, NY (US);
Xiang-Yang Wang, Buffalo, NY (US);
Health Research, Inc., Buffalo, NY (US);
Abstract
Pharmaceutical compositions comprising a stress protein complex and related molecules encoding or cells presenting such a complex are provided. The stress protein complex comprises an hsp110 or grp170 polypeptide complexed with an immunogenic polypeptide. The immunogenic polypeptide of the stress protein complex can be associated with a cancer or an infectious disease. The pharmaceutical compositions of the invention can be administered to a subject, thereby providing methods for inhibiting-infection, for inhibiting tumor growth, for inhibiting the development of a cancer, and for the treatment or prevention of infectious disease. The invention further provides a method for producing T cells directed against a tumor cell or a-infected cell, wherein a T cell is contacted with an APC that is modified to present an hsp110 or grp170 polypeptide and an immunogenic polypeptide associated with a tumor or with the-infected cell. Included in the invention are T cells produced by this method and a pharmaceutical composition comprising such T cells. The T cells can be contacted with a-infected cell in a method for killing a-infected cell, or with a tumor cell in a method for killing a tumor cell.